Immunocore announces upcoming
presentation and posters at ESMO 2023
Long-term survival data for KIMMTRAK in
previously untreated patients with metastatic uveal melanoma to be
presented as a late-breaking abstract in a mini oral session
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn.
& ROCKVILLE, Md, 07 October 2023) Immunocore Holdings plc
(Nasdaq: IMCR), a commercial-stage biotechnology company pioneering
the development of a novel class of T cell receptor (TCR)
bispecific immunotherapies designed to treat a broad range of
diseases, including cancer, infectious diseases and autoimmune
conditions, will present three-year Phase 3 survival data for
KIMMTRAK in metastatic uveal melanoma at the European Society for
Medical Oncology (ESMO) Congress 2023 commencing on 20 October.
In addition to the oral presentation, the
company will present three posters sharing data on the effect of
subsequent therapies, including checkpoint inhibitors, on overall
survival from KIMMTRAK treatment for metastatic uveal melanoma; the
reprogramming effect of KIMMTRAK on immunosuppressive M2
macrophages; and the lack of impact of BRAF mutation on KIMMTRAK
treatment in advanced cutaneous melanoma.
Presentation and poster details
Title: Three-year survival with tebentafusp in
previously untreated metastatic uveal melanoma in a phase 3 trial
(LBA50)Presenting author: Sophie
Piperno-NeumannSession: Mini oral session –
Melanoma and other skin tumours, Saturday 21 October, 2023
Title: Tebentafusp reprograms immunosuppressive
tumor-associated M2 macrophages towards anti-tumoral M1 macrophages
(2238P)Presenting author: Josep M.
PiulatsSession: Poster display, Saturday 21
October, 2023
Title: BRAF mutation status does not impact
outcomes with tebentafusp in advanced cutaneous
melanomaPresenting author: Alexander N.
ShoushtariSession: Poster display, Sunday 22
October, 2023
Title: Effect of subsequent therapies including
checkpoint inhibitors on overall survival in a phase 3 randomized
trial of tebentafusp in first line metastatic uveal melanoma:
long-term follow upPresenting author: Marlana
OrloffSession: Poster display, Sunday 22 October,
2023
##
About ImmTAC® molecules for cancerImmunocore’s
proprietary T cell receptor (TCR) technology generates a novel
class of bispecific biologics called ImmTAC (Immune mobilizing
monoclonal TCRs Against Cancer) molecules that are designed to
redirect the immune system to recognize and kill cancerous cells.
ImmTAC molecules are soluble TCRs engineered to recognize
intracellular cancer antigens with ultra-high affinity and
selectively kill these cancer cells via an anti-CD3
immune-activating effector function. Based on the demonstrated
mechanism of T cell infiltration into human tumors, the ImmTAC
mechanism of action holds the potential to treat hematologic and
solid tumors, regardless of mutational burden or immune
infiltration, including immune “cold” low mutation rate tumors.
About KIMMTRAK®KIMMTRAK is a
novel bispecific protein comprised of a soluble T cell receptor
fused to an anti-CD3 immune-effector function. KIMMTRAK
specifically targets gp100, a lineage antigen expressed in
melanocytes and melanoma. This is the first molecule developed
using Immunocore’s ImmTAC technology platform designed to redirect
and activate T cells to recognize and kill tumor cells. KIMMTRAK
has been approved for the treatment of HLA-A*02:01-positive adult
patients with unresectable or metastatic uveal melanoma in the
United States, European Union, Canada, Australia, and the United
Kingdom.
About Phase 3 IMCgp100-202 TrialIMCgp100-202
(NCT03070392) is a randomized pivotal trial that evaluated overall
survival (OS) of KIMMTRAK compared to investigator’s choice (either
pembrolizumab, ipilimumab, or dacarbazine) in HLA-A*02:01-positive
adult patients with previously untreated mUM. KIMMTRAK demonstrated
an unprecedented OS benefit with a Hazard Ratio (HR) in the
intent-to-treat population favoring KIMMTRAK, HR=0.51 (95% CI:
0.37, 0.71); p< 0.0001, over investigator’s choice (82%
pembrolizumab; 13% ipilimumab; 6% dacarbazine).
Forward Looking Statements This
press release contains “forward-looking statements” within the
meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Words such as “may,” “can,” “will,”
“believe,” “expect,” “plan,” “anticipate,” and similar expressions
(as well as other words or expressions referencing future events or
circumstances) are intended to identify forward-looking statements.
All statements, other than statements of historical facts, included
in this press release are forward-looking statements. These
statements include, but are not limited to, statements regarding
the therapeutic potential and expected clinical benefits of our
product candidates, including overall survival benefit;
expectations regarding the effect of tebentafusp on
immunosuppressive M2 macrophages; expectations indicating the lack
of impact of BRAF mutation on tebentafusp treatment in advanced
cutaneous melanoma. Any forward-looking statements are based on
management’s current expectations of future events and are subject
to a number of risks and uncertainties that could cause actual
results to differ materially and adversely from those set forth in
or implied by such forward-looking statements, many of which are
beyond Immunocore’s control.
These risks and uncertainties include, but are
not limited to, the impact of worsening macroeconomic conditions on
Immunocore’s business, strategy, financial position and anticipated
milestones, including Immunocore’s ability to conduct ongoing and
planned clinical trials; Immunocore’s ability to obtain a clinical
supply of current or future product candidates, or commercial
supply of KIMMTRAK or any future approved products, including as a
result of the COVID-19 pandemic, war in Ukraine or global
geopolitical tension; Immunocore’s ability to obtain and maintain
regulatory approval of its product candidates, including KIMMTRAK;
Immunocore’s ability and plans in continuing to establish and
expand a commercial infrastructure and to successfully launch,
market and sell KIMMTRAK and any future approved products;
Immunocore’s ability to successfully expand the approved
indications for KIMMTRAK or obtain marketing approval for KIMMTRAK
in additional geographies in the future; the delay of any current
or planned clinical trials, whether due to patient enrollment
delays or otherwise; Immunocore’s ability to successfully
demonstrate the safety and efficacy of its product candidates and
gain approval of its product candidates on a timely basis, if at
all; competition with respect to market opportunities; unexpected
safety or efficacy data observed during pre-clinical studies or
clinical trials; actions of regulatory agencies, which may affect
the initiation, timing and progress of Immunocore’s clinical trials
or future regulatory approval; Immunocore’s need for and ability to
obtain additional funding, on favorable terms or at all, including
as a result of worsening macroeconomic conditions, including
changes in inflation and interest rates and unfavorable general
market conditions, and the impacts thereon of the COVID-19
pandemic, war in Ukraine and global geopolitical tension;
Immunocore’s ability to obtain, maintain and enforce intellectual
property protection for KIMMTRAK or any product candidates it is
developing; and the success of Immunocore’s current and future
collaborations, partnerships or licensing arrangements. These and
other risks and uncertainties are described in greater detail in
the section titled "Risk Factors" in Immunocore’s filings with the
Securities and Exchange Commission, including Immunocore’s most
recent Annual Report on Form 20-F for the year ended December 31,
2022 filed with the Securities and Exchange Commission on March 1,
2023, as well as discussions of potential risks, uncertainties, and
other important factors in Immunocore’s subsequent filings with the
Securities and Exchange Commission. All information in this press
release is as of the date of the release, and Immunocore undertakes
no duty to update this information, except as required by law.
CONTACT: Immunocore
Sébastien Desprez, Head of CommunicationsT: +44 (0) 7458030732 E:
sebastien.desprez@immunocore.com Follow on Twitter and LinkedIn:
@Immunocore
Investor Relations Clayton Robertson,
Head of Investor RelationsT: +1 (215) 384-4781E:
clayton.robertson@immunocore.com
Immunocore (NASDAQ:IMCR)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Immunocore (NASDAQ:IMCR)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024